N/A Completed N=40 Randomized Treatment

Ablation Targets of Scar-related Ventricular Tachycardia Identified by Dynamic Functional Substrate Mapping

Tachycardia, Ventricular

Source: ClinicalTrials.gov NCT05086510 ↗

Enrolled (actual)

Serious AEs

15.0%

Results posted

Feb 2024

Primary outcomePrimary: Number of Participants With Recurrence of Ventricular Tachycardia — 13; 13 Participants

Summary

This study aims at comparing the recurrence rates of ventricular tachycardia ablated after being mapped by 2 different techniques.

Outcome Measures

Outcome	Result	p-value
PRIMARY Number of Participants With Recurrence of Ventricular Tachycardia	13; 13	—
SECONDARY Number of Participants Who Experience Cardiac Death	5; 4	—
SECONDARY Number of Participants Who Die From Any Cause (All-cause Mortality)	5; 4	—

Eligibility Criteria

Inclusion Criteria

• Patients with structural heart disease; previous myocardial infarction, left ventricular dilatation/systolic dysfunction, or normal left ventricular diameters/ systolic function with evidence of ventricular scar on contrast enhanced-cardiac magnetic resonance or electroanatomic map.
Sustained monomorphic ventricular tachycardia documented by 12-lead ECG or implantable cardioverter defibrillator (electrograms resistant to antiarrhythmic drug treatment or requiring implantable cardioverter defibrillator therapies.

Exclusion Criteria

• Patients with ventricular arrhythmias attributed to reversible causes.

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT05086510). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.